Browse > Article
http://dx.doi.org/10.22643/JRMP.2019.5.1.61

Synthesis and evaluation of metal purine-type complexes for lung cancer imaging  

Kang, Kyeung Jun (Division of Applied RI, Korea Institute of Radiological and Medical Sciences)
Ko, In Ok (Division of Applied RI, Korea Institute of Radiological and Medical Sciences)
Park, Ji-Ae (Division of Applied RI, Korea Institute of Radiological and Medical Sciences)
Kim, Jung Young (Division of Applied RI, Korea Institute of Radiological and Medical Sciences)
Publication Information
Journal of Radiopharmaceuticals and Molecular Probes / v.5, no.1, 2019 , pp. 61-68 More about this Journal
Abstract
Purine type compounds has been recently reported to cause the death for lung cancer cell, related to microtubules-targeting agents (MTAs). Therefore it can be used to develop as theranostic radiopharmceuticals in nuclear medicine or gadolinium-based MRI imaging agents by chelate chemistry. In the study, we tried to chemically bind a DOTA chelate on the end of purine compound and obtained a specific conjugate of DOTA-purine for metal coordination. In particular, radiometal like Cu-64, for the development of MRI imaging agents, can be utilized to choice good candidates before the synthesis of gadolinium complexes. By the screening of radioisotope technique, Gd-DOTA-purine type complex was successfully prepared and showed MRI imaging for lung cancer cell into the mouse model.
Keywords
Purine; Lung cancer; Cu-64; Gd; PET/MRI;
Citations & Related Records
연도 인용수 순위
  • Reference
1 국가암등록 통계사업, 2018년, 보건복지부
2 Lopez-Ayllon BD, Moncho-Amor V, Abarrategi A, Ibanez de Caceres I, Castro-Carpeno J, Belda-Iniesta C, Perona R, Sastre L. Cancer stem cells and cisplatin-resistant cells isolated from non-small-lung cancer cell lines constitute related cell populations. Caner Med 2014;3:1099-1111.
3 Kuo TC, Li LW, Pan SH, Fang JM, Liu JH, Cheng TJ, Wang CJ, Hung PF, Chen HY, Hong TM, Hsu YL Wong CH, Yang PC. Purine-Type Compounds Induce Microtubule Fragmentation and Lung Cancer Cell Death through Interaction with Katanin. J Med Chem 2016;59:8521-8534.   DOI
4 Wahsner J, Gale EM, Rodriguez-Rodriguez A. Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers. Chem Rev 2019;119:957-1057.   DOI
5 Jeong Y, Hwang HS, Na K. Theranostics and contrast agents for magnetic resonance imaging. Biomater Res 2018;22:20.   DOI
6 Park JA, Kim JY. Recent advances in radiopharmaceutical application of matched-pair radiometals. Curr Top Med Chem 2013;13:458-469.   DOI
7 Romei C, Turturici L, Tavanti L, Miedema J, Fiorini S, Marletta M, Wielopolski P, Tiddens H, Falaschi F, Ciet P. The use of chest magnetic resonance imaging in interstitial lung disease: a systematic review. Eur Respir Rev 2018;27:180062.   DOI
8 Kim HK, Lee GH, Chang Y. Gadolinium as an mri contrast agent. Future Med Chem 2018;10:639-661.   DOI
9 Park JA, Kim JY, Kim HK, Lee W, Lim SM, Chang Y, Kim TJ, Kim KM. Heteronuclear Gd-$^{(99m)}Tc$ Complex of DTPA-Bis(histidylamide) Conjugate as a Bimodal MR/SPECT Imaging Probe. ACS Med Chem Lett 2012;3:299-302.   DOI
10 Jung KH, Park JA, Kim JY, Kim MH, Oh S, Kim HK, Choi EJ, Kim HJ, Do SH, Lee KC, Kim KM, Lee YJ, Chang Y. Image-Guided Neutron Capture Therapy Using the Gd-DO3A-BTA Complex as a New Combinatorial Treatment Approach. Contrast Media Mol Imaging 2018: 3727109.   DOI